The Foundation supports research that can lead to the creation of better Parkinson's treatments. Here you can search previously awarded grants by keyword, program name, researcher name, institution or organization name and/or year.
FUNDED GRANTS ( 88)
LRRK2 Biology Consortium, 2018
Parkinson's disease (PD) affects nearly any body system, as evidenced by the diversity of its symptoms. While its non-motor symptoms, such as olfactory dysfunction, rapid eye movement sleep behavior disorder (RBD) and gastrointestinal (GI) abnormalities, do not define the disease, they have a large impact on those living with it. In this project, we will use a pre-clinical model o...
Researchers: R. Jeremy Nichols, PhD
Therapeutic Pipeline Program, 2018
Many people with Parkinson's disease (PD) have an abnormal glucocerebrosidase (GBA) enzyme, which causes them to accumulate fatty acids -- chemicals that make up fat -- in the brain and other organs. The exact relationship between Parkinson's and GBA abnormalities is unclear. Recent research findings suggest that replacing the abnormal, dysfunctional GBA with its functional form de...
Researchers: Jennyfer Bultinck, PhD
Improved Biomarkers and Clinical Outcome Measures, 2017
Using Automatic Acoustic Speech Analysis and REM Sleep Behavior Disorder to Detect Individuals at High Risk of Parkinson's Disease and Other Alpha-synucleinopathies
Speech is an important indicator of motor function and movement coordination and can be extremely sensitive to the progression of neurologic diseases. The aim of this project is to use simple speech recording and high-end pattern analysis to detect pre-clinical stages of disabling central nervous system disorders including Parkinson's disease (PD) and other alpha-synucleinopathies...
Researchers: Jan Rusz, PhD
Research Grant, 2017
The US Food and Drug (FDA) requires acceptable outcome measures to approve a cognitive-enhancing medication for the treatment of mild cognitive impairment (MCI) in Parkinson's disease (PD). The FDA has indicated that the Clinical Dementia Rating Scale Sum of Boxes (CDR-SOB) is an acceptable combined cognitive-functional outcome for use in clinical trials; however, the CDR-SOB has ...
Researchers: Daniel Weintraub, MD
Research Grant, 2017
Dystonia and Parkinson's disease (PD) are closely related movement disorders. Dystonia is characterized by painful, prolonged muscle contractions that cause involuntary, repetitive twisting and sustained muscle contractions. Some experts estimate that 40 percent of people with PD experience dystonia as an early symptom or complication of treatment. Deep brain stimulation (DBS) is ...
Researchers: Harrison C. Walker, MD